The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Phase 2 Completed 72 enrolled Wits Health Consortium (Pty) Ltd Imperial College London · collab Karolinska Institutet · collab King's College London · collab London School of Hygiene and Tropical Medicine · collab MRC/UVRI Uganda Research Unit · collab University of Cape Town · collab University of Liverpool · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

To compare the effect of different PrEP drugs (FTC-TDF and FTC-TAF), doses and timing of doses on p24 antigen level in resected foreskin tissue following HIV exposure ex vivo challenge.

Timeline

Start: 2019-11-11
Primary completion: 2021-02-25
Completion: 2021-02-25

Publications

Nash S, Dietrich J, Ssemata AS, Herrera C, O'Hagan K, Else L, Chiodi F, Kelly C, Shattock R, Chirenje M, Lebina L, Khoo S, Bekker LG, Weiss HA, Gray C, Stranix-Chibanda L, Kaleebu P, Seeley J, Martinson N, Fox J; CHAPS team. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. Trials. 2020 Oct 30;21(1):900. doi: 10.1186/s13063-020-04760-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tenofovir	Small molecule	—	Oral

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Summary

Timeline

Publications

Drugs

Indications